PLK1 and breast carcinoma: The homing ability of subcutaneous ASCs toward the breast cancer cell lines MCF-7 and MDA-MB-231 showed a significant decrease even after the short time treatment with Plk1 inhibitors (Figure 7A and 7B), supporting the results of the impaired migration behavior obtained by the single cell tracking assay (Figure 6A–6E).